HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare - A Pair Trade: Long Sino Biopharm (1177.HK), Short Hengrui Medicine (600276.CH)

Sichuan Kelun Pharmaceutical (002422.CH) - The Deal with Merck Brightens the Outlook; A Dark Horse?

Pre-IPO Shanghai Chicmax Cosmetic - PHIP Updates: Declining Performance and Challenging Outlook

Pre-IPO Giant Biogene - The Strength and the Concerns

Bloomage Biotechnology (688363.CH) Vs Imeik Technology (300896.CH) - The Logic and the Outlook

Bloomage Biotechnology (688363.CH) - Positioning and Strategic Layout Imply Strong Upside Potential

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

<ul>
<li>Although the recombinant collagen with relatively low price is “subversive” in the preparation process, animal-derived collagen is still more widely used, covering larger markets with various products. </li>
<li>Either for business diversification or to avoid policy risks, how to explore the second growth point is important to Giant Biogene.Otherwise,the Company's hard to improve the resilience to market/policy changes.</li>
<li>Bloomage would have higher valuation expansion potential than Giant Biogene in mid- to long-term. In other words, if the valuation of Giant Biogene is higher than Bloomage, there’s overvaluation risk.</li>
</ul>


Although the recombinant collagen with relatively low price is “subversive” in the preparation process, animal-derived collagen is still more widely used, covering larger markets with various products. 
Either for business diversification or to avoid policy risks, how to explore the second growth point is important to Giant Biogene.Otherwise,the Company's hard to improve the resilience to market/policy changes.
Bloomage would have higher valuation expansion potential than Giant Biogene in mid- to long-term. In other words, if the valuation of Giant Biogene is higher than Bloomage, there’s overvaluation risk.


Yunnan Botanee Bio-Technology (300957 CH)

Pre-IPO Giant Biogene (2367 HK) - Some Unstable Factors